Avantor (AVTR) Stock Analysis & Winston Score
Avantor makes and sells the materials, chemicals, and equipment that scientists need to do their work. Its customers are pharmaceutical companies, biotech firms, hospitals, and university labs. The company supplies things like lab chemicals, filters, and single-use plastic components used in drug manufacturing and research. Avantor earns money by selling these supplies and materials directly to customers, often through long-term contracts and repeat orders. It operates globally, with a large presence in North America and Europe, and generates roughly $6–7 billion in annual revenue. Its competitive edge comes from deep relationships with drug manufacturers and a broad product catalog that makes it easier for customers to buy from one supplier rather than many. The main risk right now is weak demand from biotech and pharmaceutical customers, who have been cutting spending since the post-pandemic boom ended, which is reflected in the company's current negative operating margin.
Winston Score: 24/100 — Weak
Weak fundamentals across most pillars.
- Quality: Mixed (9/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (2/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Mixed (6/15)
Key Facts
Price: $11.07
Market Cap: $7.6B
Sector: Healthcare
Industry: Medical - Instruments & Supplies


